BEST OF ONCOLOGY WEST 2024: Lung Cancer – Dr. Barb Melosky
OR
Chair
Dr. Sharlene Gill
Dr. Daniel Heng
Panelist
Dr. Barb Melosky
Studies/trials discussed:
- Osimertinib in Resected EGFR-Mutated Non–Small-Cell Lung Cancer
- ALINA: A phase III study of alectinib versus chemotherapy as adjuvant therapy in patients with stage IB–IIIA anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC).
- Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
- Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer
- Perioperative Durvalumab for Resectable Non–Small-Cell Lung Cancer
- Perioperative Pembrolizumab for Early-Stage Non–Small-Cell Lung Cancer
- LBA1 CheckMate 77T: Phase III study comparing neoadjuvant nivolumab (NIVO) plus chemotherapy (chemo) vs neoadjuvant placebo plus chemo followed by surgery and adjuvant NIVO or placebo for previously untreated, resectable stage II–IIIb NSCLC
- Patient-reported outcomes from FLAURA: Osimertinib versus erlotinib or gefitinib in patients with EGFR-mutated advanced non-small-cell lung cancer
- Updated Analysis of NEJ009: Gefitinib-Alone Versus Gefitinib Plus Chemotherapy for Non–Small-Cell Lung Cancer With Mutated EGFR
- Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC
- MARIPOSA: phase 3 study of first-line amivantamab + lazertinib versus osimertinib in EGFR-mutant non-small-cell lung cancer
- Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study
- ORR Study Design
- Amivantamab in EGFR Exon 20 Insertion–Mutated Non–Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study
- Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions
